{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:42Z","timestamp":1793922642787,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ymgme.2009.08.003","type":"journal-article","created":{"date-parts":[[2009,8,23]],"date-time":"2009-08-23T08:23:48Z","timestamp":1251015828000},"page":"26-33","source":"Crossref","is-referenced-by-count":336,"title":["Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants"],"prefix":"10.1016","volume":"99","author":[{"given":"Priya S.","family":"Kishnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"DeArmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ann","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-T","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2009.08.003_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2009.08.003_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.08.003_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.08.003_bib4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe Disease by newborn screening is feasible: results from the Taiwan screening program","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.08.003_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1432-1033.1995.903_a.x","article-title":"Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase","volume":"234","author":"Fuller","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymgme.2009.08.003_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2009.08.003_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2009.08.003_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00125817-200103000-00008","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2009.08.003_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","article-title":"Electrocardiographic response to enzyme replacement therapy for Pompe disease","volume":"8","author":"Ansong","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2009.08.003_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ymgme.2007.04.018","article-title":"Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease","volume":"91","author":"Hawes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.08.003_bib14","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.08.003_bib15","series-title":"Motor assessment of the developing infant","author":"Piper","year":"1994"},{"key":"10.1016\/j.ymgme.2009.08.003_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2009.08.003_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2009.08.003_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2009.08.003_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ymgme.2009.08.003_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02238520","article-title":"Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children","volume":"12","author":"Vogel","year":"1991","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022998010833","article-title":"Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice","volume":"12","author":"Raben","year":"2003","journal-title":"Transgenic. Res."},{"key":"10.1016\/j.ymgme.2009.08.003_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.08.003_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.08.003_bib25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","article-title":"Factor VIII gene inversions in severe hemophilia A: results of an international consortium study","volume":"86","author":"Antonarakis","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2009.08.003_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00043426-199701000-00003","article-title":"Factor IX inhibitors and anaphylaxis in hemophilia B","volume":"19","author":"Warrier","year":"1997","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0027-5107(01)00232-9","article-title":"Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase","volume":"483","author":"Germain","year":"2001","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ymgme.2009.08.003_bib28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2009.08.003_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.08.003_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"issue":"Suppl. 6","key":"10.1016\/j.ymgme.2009.08.003_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymgme.2009.08.003_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.0305480101","article-title":"Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"101","author":"Kakkis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2009.08.003_bib33","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.4049\/jimmunol.173.7.4715","article-title":"Induction of immunological tolerance\/hyporesponsiveness in baboons with a nondepleting CD4 antibody","volume":"173","author":"Winsor-Hines","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2009.08.003_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1309\/RLNM-J01W-BJRN-LH03","article-title":"Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP","volume":"125","author":"Darabi","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymgme.2009.08.003_bib39","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2009.08.003_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.gim.0000217781.66786.9b","article-title":"Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease","volume":"8","author":"Zhang","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2009.08.003_bib42","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe Disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209002443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209002443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T17:15:54Z","timestamp":1590081354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719209002443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1096719209002443"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}